NYC startup
fromFortune
10 hours agoFrom drought to demand: Biotech IPOs roar back with Kailera and Alamar | Fortune
Investors are returning to biotech IPOs, as demonstrated by Alamar Biosciences and Kailera Therapeutics' successful public offerings.